南宁市HIV-1/AIDS人群治疗前pol区遗传特性及蛋白结构分析

为探讨南宁市某县艾滋病病毒1型(HIV-1)感染人群中治疗前pol区遗传特性及蛋白结构变化情况,本研究通过RT-PCR扩增pol区部分序列并进行测序,将序列同源比对构建系统进化树;分型确定毒株亚型和斯坦福大学HIV耐药性数据库比对,分析耐药相关位点;SWISS-MODEL蛋白质同源数据库进行建模分析氨基酸的突变对蛋白质结构和功能的影响。本研究在90份HIV-1标本中获得46个pol区有效序列,共发现4种亚型,其中CRF01_AE占76.08%(35/46)、CRF08_BC占15.22%(7/46)、CRF07_BC占(3/46)6.52%、CRF59_01B1占2.17%(1/46);46个序列中有4例(8.69%)出现耐药突变位点,没有针对核苷酸反转录酶抑制剂(NRTI)的耐药突变;针对蛋白酶类抑制剂(PIs)1例,PR蛋白酶的柔性部位I47V位点发生突变,β折叠结构的I84V位点发生突变,都是异亮氨酸突变为缬氨酸;针对非核苷酸反转录酶抑制剂(NNRTI)有3例,2例位于活性中心的Y181C位点由酪氨酸突变为半胱氨酸,1例位于转角处的E138G位点由谷氨酸突变为甘氨酸。研究表明,南宁市某县HIV-1病毒CRF01_AE重组亚型比例最大,未经抗病毒治疗HIV1感染者中已经出现pol区耐药突变株,突变位点主要位于活性中心及柔性部位,传播水平已经处于中等流行状态。深入分析蛋白质与抑制剂相互作用机制,有助于为艾滋病抗病毒及耐药性监测方案提供科学依据。     

上海地区HIV毒株基因亚型分布及原发基因耐药的分子流行病学研究

本文通过对未经抗病毒治疗患者的人类免疫缺陷病毒1型（HIV-1）毒株进行检测,了解上海地区HIV-1的亚型分布及原发耐药基因变异现状。对118例未经治疗的HIV感染者其标本中HIV蛋白酶全长和部分反转录酶基因进行反转录-聚合酶链反应（RT-PCR）扩增,经DNA测序后进行系统进化树分析和重组分析,以确定HIV-1基因亚型和重组体,并与斯坦福耐药数据库比对,了解耐药性突变位点。使用斯坦福REGA HIV亚型分型工具和美国国立生物技术信息中心（NCBI）HIV亚型分析工具分析亚型,获得118例患者的HIV基因序列,基因分型分别为CRF01_AE重组体57例(48.3%)、B亚型36例(30.5%)、CRF07_BC 15例 (12.7%)、CRF08_BC 7例(5.9%)、C亚型2例(1.7%),亚型间或重组体间二重重组体(B/CRF01_A E)1例(0.8%)。蛋白酶抑制剂(PI)和反转录酶抑制剂相关的耐药基因突变率达54.2%（64/118）,其中2例（1.7%）发生PI耐药,基因突变位点：M46L、Q58E。5例(4.1%)对反转录酶抑制剂产生耐药,其中对核苷类反转录酶抑制剂（NRTI）和非核苷类反转录酶抑制剂（NNRTI）的耐药率分别为3例(2.4%)和5例(4.1%)。基因突变位点：NRTI为M41L、D67N、T69I/N/S、K70L、L74V、V75L、V118I、M184V、L210W/F/M/S和T215F;NNRTI为V90I、L100V、K103R/N、V106M/P/I/G、E138G/A、V179E/D/T、Y181C、G190A、H221Y、F227L、K238S和Y318F。结果提示,上海地区HIV毒株以CRF01_AE重组亚型为主,且发现新的重组体,可能出现新重组体流行的趋势。PI和反转录酶抑制剂相关的耐药基因突变率较高,且存在高度原发耐药毒株,应加强HIV-1耐药基因变异监测,科学、合理地给予抗病毒治疗。     

河南郑州市男男同性恋HIV-1感染者gag区基因亚型分析

为了解河南郑州市男男同性恋人群HIV-1流行株的亚型分布情况,运用反转录及套式PCR方法从40例已经被确认为HIV-1阳性的MSM的全血样本中扩增gag全长基因并进行序列测定,应用BioEdit软件对序列进行校对编辑,利用MEGA3.1软件构件系统进化树,同时使用美国Los Alamos国家实验室HIV核酸序列库和美国NCBI提供的在线分析工具进行比对分析,确定基因亚型。结果成功获得24条gag基因序列,亚型分析结果显示,共存在B、CRF01-AE和CRF07-BC三种亚型,其中B亚型8例（33.33﹪）,CRF01-AE亚型10例（41.67﹪）,CRF07-BC亚型6例（25﹪）。小样本量的流行病学调查显示,河南郑州市同性恋人群中主要存在B,CRF01-AE和CRF07-BC三种亚型,CRF01-AE已成为河南郑州市MSM人群中HIV主要流行亚型,河南地区重组型毒株逐渐占优势,流行情况更加复杂。     

沈阳市人类免疫缺陷病毒的基因序列分析

从10份沈阳地区人类免疫缺陷病毒1型(HIV-1)血浆标本中提取核糖核酸(RNA),经逆转录聚合酶链反应(RT-PCR)和套式聚合酶链反应(nest-PCR)扩增HIV-1的p17与p24交界部分的基因片断并进行测序。将所测序列与各亚型国际参考株及亚洲流行参考序列进行比对,确定被检标本的亚型,并进行基因序列分析。同时将所得亚型结果与经过亚型特异性引物的复合套氏PCR鉴定基因亚型的方法所获结果进行比较。结果表明,10份HIV-1病毒株分属B′、CRF07-BC和CRF01-AE3种基因亚型。本文所研究样本的p17区段的ks/ka值小于1,而p24区段的ks/ka值大于1;p24部分的基因同源性高于p17部分,即我国HIV-1B′、CRF07-BC和CRF01-AE3种亚型毒株的p17区段的基因变异较大,而p24区段相对较为保守。提示上述3种亚型HIV-1病毒株的p24区段更适合于HIV-1疫苗的研制。     

沈阳市人类免疫缺陷病毒的基因序列分析

从10份沈阳地区人类免疫缺陷病毒1型(HIV-1)血浆标本中提取核糖核酸(RNA),经逆转录聚合酶链反应(RT-PCR)和套式聚合酶链反应(nest-PCR)扩增HIV-1的p17与p24交界部分的基因片断并进行测序.将所测序列与各亚型国际参考株及亚洲流行参考序列进行比对,确定被检标本的亚型,并进行基因序列分析.同时将所得亚型结果与经过亚型特异性引物的复合套氏PCR鉴定基因亚型的方法所获结果进行比较.结果表明,10份HIV-1病毒株分属B'、CRF07-BC和CRF01-AE 3种基因亚型.本文所研究样本的p17区段的ks/ka值小于1,而p24区段的ks/ka值大于1;p24部分的基因同源性高于p17部分,即我国HIV-1 B'、CRF07-BC和CRF01-AE 3种亚型毒株的p17区段的基因变异较大,而p24区段相对较为保守.提示上述3种亚型HIV-1病毒株的p24区段更适合于HIV-1疫苗的研制.     

人类免疫缺陷病毒1型耐药基因的监测

2001年12月在美国举行的第41届ICAAC年会上公布的研究结果显示,美国78％的成人人类免疫缺陷病毒1型(HIV-1)感染者中存在着对一种或多种抗反转录病毒(ARV)药物耐药的病毒株。其中,对核苷类反转录酶抑制剂(NRTI)的耐药率最高,为……     

新余市CRF01-AE亚型人类免疫缺陷病毒的分子流行病学及其抗病毒治疗的研究

为了分析新余市HIV-1 CRF01-AE亚型的变异特征,了解其流行特性和最适抗逆转录病毒治疗方案,提高疗效,本文通过提取HIV毒株的RNA,巢式PCR扩增其env基因,产物经纯化测序,获得序列;对达到抗病毒治疗标准的HIV感染者,用不同治疗方案治疗至少6个月,并每隔3个月进行CD4+T淋巴细胞计数,获得治疗方案与疗效的关系。结果发现,经异性性接触感染的CRF01-AE亚型毒株间基因距离较大(0~47.4%),分为两大支,而同性性接触感染株较集中,基因距离小(0~2.6%);CRF01-AE亚型感染者合并乙肝、丙肝和梅毒感染率较高(56.3%);该型感染者经不同抗病毒治疗方案短期治疗后,CD4+T淋巴细胞水平都逐渐上升,但上升水平差异显著(p0.05)。可见,HIV-1 CRF01-AE亚型毒株在传播过程中产生了各自的变异特征,且在新余市成为优势株而不断扩散,其感染者合并其它病毒感染率高,机会性感染大。HIV-1 CRF01-AE亚型毒株对治疗方案具有选择性,临床尽量选择最佳治疗方案,少用方案AZT+NVP+3TC,以提高疗效,降低机会感染率。     

柳州和南宁HIV-1亚型分布及耐药情况调查

为了解柳州和南宁两市HIV-1亚型分布和耐药情况,在柳州和南宁招募HIV感染者和AIDS患者共304名,采集外周静脉血,从血浆中提取HIVRNA,扩增HIVpol基因并测序。将获得的序列进行系统进化树分析,结果表明柳州的HIV-1毒株中存在CRF01_AE和CRF07_BC两种亚型,其中CRF01_AE毒株占75.2%,CRF07_BC毒株占24.8%;南宁的HIV-1毒株中存在CRF01_AE、CRF08_BC、B亚型和C亚型共4种亚型,其中CRF01_AE和CRF08_BC仍是南宁最主要的亚型,CRF01_AE占85.8%,CRF08_BC占11.5%。根据所得的序列资料进行HIV-1耐药性分析,计算耐药率。计算结果表明,柳州未治疗和治疗研究对象的耐药率分别为3.3%和8.7%,南宁未治疗和治疗研究对象的耐药率分别为1.4%和27.5%。     

2020年银川市HIV-1感染者基因亚型及耐药分析

为了解银川市接受抗病毒治疗的HIV-1感染者基因亚型和耐药突变特征。收集2020年银川市接受抗病毒治疗的HIV-1感染者血样,其中病毒载量大于400拷贝/mL的样本进行基因型耐药检测,通过巢式聚合酶链反应（PCR）扩增HIV-1 pol基因区片段并测序,对所得序列进行基因分型和耐药突变分析。收集642例血浆样本,50例病毒载量大于400拷贝/mL,基因型耐药检测后获得29例pol区基因序列。17例耐药,3例潜在耐药,总体耐药率为2.65%(17/642)。CRF07＿BC和CRF01＿AE是耐药株的主要基因亚型。NRTIs类耐药突变中,M184V/I(31.03%)突变发生率最高,其次为K65R(17.24%)。3TC、FTC和ABC耐药发生率最高,均为37.93%(11/29)。NNRTIs类耐药突变中,G190A/S/E、V179D/DE/E突变发生率最高,均为24.14%;K103N/KN(17.24%)次之。EFV和NVP耐药发生率最高,均为58.62%(17/29)。2020年银川市新型重组亚型增加,首次检出CRF79＿0107。总体耐药率处于低水平,以NNRTIs耐药为主,...     

CRF01-AE亚型人类免疫缺陷病毒的基因序列特征研究

从确诊的HIV-1感染者的全血样本中提取基因组DNA,经套式聚合酶链反应(PCR)扩增其gag蛋白P17/P24交界区基因片断后,将扩增产物进行纯化和测序,分析其氨基酸序列。进而了解所检出的病毒基因变异和分子流行病学特征。结果发现,HIV-1 CRF01-AE亚型病毒分别与3株不同来源的国际参考毒株具有紧密的亲缘关系,表明这些毒株可能分别由不同的传播路线进入我国大陆境内。     

HIV-1抗体阳性血浆中HIV-1病毒基因分型研究

为了解HIV抗体阳性血浆中的HIV-1病毒基因亚型的情况,应用逆转录PCR和DNA序列测定技术,对6份获自高危人群的抗HIV-1阳性血浆进行序列分析和基因亚型分型的研究,结果表明均属HIV-1B亚型.V3环氨基酸序列分析指出这些HIV-1B亚型病毒株与泰国HIV-1B亚型病毒株核苷酸和氨基酸序列相似;同时发现HIV-1 cDNA和氨基酸序列均相同,推测这6份标本可能来自同时感染同一株HIV病毒的感染者.本研究对了解高危人群中HIV-1流行的遗传变异和HIV-1亚型病毒株的分子流行病分析具有一定的意义.     

Glutamate metabolism in HIV-1 infected macrophages: Role of HIV-1 Vpr

HIV-1 infected macrophages play a significant role in the neuropathogenesis of AIDS. HIV-1 viral protein R (Vpr) not only facilitates HIV-1 infection but also contribute to long-lived persistence in macrophages. Our previous studies using SILAC-based proteomic analysis showed that the expression of critical metabolic enzymes in the glycolytic pathway and tricarboxylic acid (TCA) cycle were altered in response to Vpr expression in macrophages. We hypothesized that Vpr-induced modulation of glycolysis and TCA cycle regulates glutamate metabolism and release in HIV-1 infected macrophages.

We assessed the amount of specific metabolites induced by Vpr and HIV-1 in macrophages at the intracellular and extracellular level in a time-dependent manner utilizing multiple reaction monitoring (MRM) targeted metabolomics. In addition, stable isotope-labeled glucose and an MRM targeted metabolomics assay were used to evaluate the de novo synthesis and release of glutamate in Vpr overexpressing macrophages and HIV-1 infected macrophages, throughout the metabolic flux of glycolytic pathway and TCA cycle activation.

The metabolic flux studies demonstrated an increase in glucose uptake, glutamate release and accumulation of α-ketoglutarate (α-KG) and glutamine in the extracellular milieu in Vpr expressing and HIV-1 infected macrophages. Interestingly, glutamate pools and other intracellular intermediates (glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), citrate, malate, α-KG, and glutamine) showed a decreased trend except for fumarate, in contrast to the glutamine accumulation observed in the extracellular space in Vpr overexpressing macrophages.

Our studies demonstrate that dysregulation of mitochondrial glutamate metabolism induced by Vpr in HIV-1 infected macrophages commonly seen, may contribute to neurodegeneration via excitotoxic mechanisms in the context of NeuroAIDS.     

HIV-1 pathogenesis

Despite considerable advances in HIV science in the past 20 years, the reason why HIV-1 infection is pathogenic is still debated and the goal of eradicating HIV-1 infection remains elusive. A deeper understanding of the interplay between HIV-1 and its host and why simian immunodeficiency virus (SIV) is nonpathogenic in some natural hosts may provide a few answers.     

Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial

Background

Most HIV-1 transmission in Africa occurs among HIV-1-discordant couples (one partner HIV-1 infected and one uninfected) who are unaware of their discordant HIV-1 serostatus. Given the high HIV-1 incidence among HIV-1 discordant couples and to assess efficacy of interventions for reducing HIV-1 transmission, HIV-1 discordant couples represent a critical target population for HIV-1 prevention interventions and prevention trials. Substantial regional differences exist in HIV-1 prevalence in Africa, but regional differences in HIV-1 discordance among African couples, has not previously been reported.

Methodology/Principal Findings

The Partners in Prevention HSV-2/HIV-1 Transmission Trial (“Partners HSV-2 Study”), the first large HIV-1 prevention trial in Africa involving HIV-1 discordant couples, completed enrollment in May 2007. Partners HSV-2 Study recruitment data from 12 sites from East and Southern Africa were used to assess HIV-1 discordance among couples accessing couples HIV-1 counseling and testing, and to correlate with enrollment of HIV-1 discordant couples. HIV-1 discordance at Partners HSV-2 Study sites ranged from 8–31% of couples tested from the community. Across all study sites and, among all couples with one HIV-1 infected partner, almost half (49%) of couples were HIV-1 discordant. Site-specific monthly enrollment of HIV-1 discordant couples into the clinical trial was not directly associated with prevalence of HIV-1 discordance, but was modestly correlated with national HIV-1 counseling and testing rates and access to palliative care/basic health care (r = 0.74, p = 0.09).

Conclusions/Significance

HIV-1 discordant couples are a critical target for HIV-1 prevention in Africa. In addition to community prevalence of HIV-1 discordance, national infrastructure for HIV-1 testing and healthcare delivery and effective community outreach strategies impact recruitment of HIV-1 discordant couples into HIV-1 prevention trials.     

Enhanced infectivity of HIV-1 by X4 HIV-1 coinfection

Two strains of human immunodeficiency virus type 1 (HIV-1) expressing different reporters, human placental alkaline phosphatase (PLAP) and murine heat stable antigen (HSA, CD24), were used for dual infection. Flow cytometric analysis enabled us to distinguish cells not only infected with individual reporter virus but also superinfected with both reporter viruses. When the CD4 positive T cell line, PM1, was dually infected by both reporter viruses with different coreceptor utilization, coinfection with CXCR4-tropic HIV-1 (X4 HIV-1) expressing one reporter increased the rate of cells infected with HIV-1 expressing another reporter. This enhancement was accompanied by an increased level of p24 antigen Gag in culture supernatant, indicating that infectivity of HIV-1 was augmented by X4 HIV-1 coinfection. The CXCR4 antagonist, T140 eliminated this enhancement, suggesting the role of X4 envelope via CXCR4. These results imply the role of X4 HIV-1 at the late stage of infection.     

HIV-1 Nef protects human-monocyte-derived macrophages from HIV-1-induced apoptosis

HIV-1 Nef is the regulatory protein expressed earliest and most abundantly in the infection cycle. Its expression has been correlated with a plethora of effects detectable either in producer, target, and bystander cells, as well as in the viral particles. Even if the relationship between Nef expression and apoptosis has been already matter of investigation in infected lymphocytes, whose resistance to HIV infection is however limited to few days, this remains to be investigated in cells that in vivo well resist the HIV cytopathic effect. In such an instance, we were interested in establishing whether Nef influences the apoptotic processes in primary human-monocyte-derived macrophages (MDM). High efficiency HIV-1 infection of MDM allowed us to establish that virus-expressed Nef strongly counteracts the HIV-1-induced apoptosis. The Nef mutant analysis suggested that this effect relies on the interaction with different protein partners and cell compartments. We also observed that the Nef protection to the HIV-1-induced apoptosis correlated with the hyper-phosphorylation and consequent inactivation of the pro-apoptotic Bad protein. On the basis of these results, we propose the Nef anti-apoptotic effect as a relevant part of the mechanism of the in vivo establishment of the HIV macrophage reservoirs.